Complementary oligonucleotides to DDHD1 and their use for cancer prevention and treatment
The present invention relates to the field of biotechnology and pharmaceuticals as it aims at the use of oligonucleotides complementary to the DDHD1 sequence, or parts of it, carried by plant extracellular vesicles(EVs), for the prevention and treatment of cancer.
The invention consists in the development of a drug delivery system of oligonucleotides, specifically those against DDHD1, based on the use of plant vesicles (from lemon juice or other plant matrices) in order to test their stability and efficacy in in vitro and in vivo cellular models. The invention would enable the development of novel biotechnological drugs based on the use of vesicles from plant matrices.
- Increased stability of oligonucleotides;
- Increased bioavailability of oligonucleotides;
- Opportunity to restrict the effect to target organs;
- Collaboration with Navhetec s.r.l, Spinoff that produces plant vesicles at industrial scale.